Prof Bertrand Tombal speaks to ecancer about the combination of darolutamide, androgen-deprivation therapy, and docetaxel in European metastatic hormone-sensitive prostate cancer patients from the phase 3 ARASENS trial.

The study found that this combination treatment increased overall survival and reduced the risk of death compared to those who received placebo, androgen deprivation therapy, and docetaxel.

Prof Tombal highlights that the darolutamide group also had higher four-year survival rates and a longer time to the development of castration-resistant prostate cancer (CRPC) and pain progression.

The study showed that darolutamide was well-tolerated in this population, with similar rates of treatment-emergent adverse events compared to those who received placebo.